Australia markets open in 8 hours 39 minutes

Pacira BioSciences, Inc. (PCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
25.72-0.33 (-1.27%)
As of 11:20AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.21B
Enterprise value 1.52B
Trailing P/E 29.27
Forward P/E 9.47
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.01
Price/book (mrq)1.39
Enterprise value/revenue 2.25
Enterprise value/EBITDA 9.83

Trading information

Stock price history

Beta (5Y monthly) 0.75
52-week change 3-43.92%
S&P500 52-week change 324.19%
52-week high 347.01
52-week low 325.33
50-day moving average 328.65
200-day moving average 331.28

Share statistics

Avg vol (3-month) 3503.33k
Avg vol (10-day) 3459.06k
Shares outstanding 546.52M
Implied shares outstanding 647.02M
Float 846M
% held by insiders 11.26%
% held by institutions 1108.12%
Shares short (15 Apr 2024) 43.45M
Short ratio (15 Apr 2024) 47.57
Short % of float (15 Apr 2024) 410.75%
Short % of shares outstanding (15 Apr 2024) 47.41%
Shares short (prior month 15 Mar 2024) 44.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 6.22%
Operating margin (ttm)18.74%

Management effectiveness

Return on assets (ttm)3.35%
Return on equity (ttm)5.10%

Income statement

Revenue (ttm)674.98M
Revenue per share (ttm)14.60
Quarterly revenue growth (yoy)5.40%
Gross profit (ttm)N/A
EBITDA 162.9M
Net income avi to common (ttm)41.95M
Diluted EPS (ttm)0.89
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)278.58M
Total cash per share (mrq)5.99
Total debt (mrq)586.04M
Total debt/equity (mrq)67.35%
Current ratio (mrq)5.24
Book value per share (mrq)18.72

Cash flow statement

Operating cash flow (ttm)154.65M
Levered free cash flow (ttm)107.15M